-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Vanglusagene ensiparvovec
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Vanglusagene ensiparvovec report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Theriva Biologics Inc’s Ribaxamase
Empower your strategies with our Net Present Value Model: Theriva Biologics Inc's Ribaxamase report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Theriva Biologics Inc’s SYN-020
Empower your strategies with our Net Present Value Model: Theriva Biologics Inc's SYN-020 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-8543 in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-8543 in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-8543 in Chronic Lymphocytic Leukemia (CLL) Drug Details: JNJ-80948543 is...
-
Product Insights
Infectious Diarrhea – Drugs In Development, 2023
Global Markets Direct’s, ‘Infectious Diarrhea - Drugs In Development, 2023’, provides an overview of the Infectious Diarrhea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Infectious Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Enteritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Enteritis - Drugs In Development, 2023’, provides an overview of the Enteritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Enteritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Diarrhea – Drugs In Development, 2023
Global Markets Direct’s, ‘Diarrhea - Drugs In Development, 2023’, provides an overview of the Diarrhea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Celiac Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Celiac Disease - Drugs In Development, 2023’, provides an overview of the Celiac Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Pertussis (Whooping Cough) – Drugs In Development, 2023
Global Markets Direct’s, ‘Pertussis (Whooping Cough) - Drugs In Development, 2023’, provides an overview of the Pertussis (Whooping Cough) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...